| Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Genomics of myelodysplastic/myeloproliferative neoplasm |
|
Seminars in Diagnostic Pathology |
Myelodysplastic Syndromes (MDS) |
| Overview of the Management of Higher-Risk Myelodysplastic Syndromes |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes |
|
Current Treatment Options in Oncology |
Myelodysplastic Syndromes (MDS) |
| Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
